For instance, CIML CAR-NK cells targeting CD19 in B-cell malignancies have shown prolonged survival and reduced tumor progression in preclinical models, highlighting the potential of this approach to improve outcomes for patients with refractory cancers. This evidence concerns the gene CD19 and neoplasm.